Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of Parkinsonism?
Nitric oxide (NO) synthase inhibitor, N-nitro-L-arginine (NNLA) produced dose-dependent, long-lasting catalepsy in rats, the effect being attenuated by NO donors L-arginine and molsidomine. Catalepsy induced by haloperidol (0.4 mg/kg i.p.), D2 receptor antagonist, was reduced dose-dependently by molsidomine (10.0-100.0 mg/kg) and by L-arginine at a dose of 100.0 mg/kg. Low, non-cataleptic doses of NNLA (0.1 mg/kg) and haloperidol (0.1 mg/kg) given in combination produced a marked and long-lasting catalepsy. The results suggest that NO plays a role in NNLA-induced catalepsy as well as in catalepsy elicited by haloperidol.
Krzaścik
P
P
Department of Pharmacology and Physiology of the Nervous System, Institute of Psychiatry and Neurology, Warszawa, Poland.
Kostowski
W
W
D000818:Animals; D001120:Arginine / Q000494:pharmacology; D002375:Catalepsy / Q000139:chemically induced* / Q000188:drug therapy; D004195:Disease Models, Animal; D006220:Haloperidol / Q000037:antagonists & inhibitors; D008297:Male; D008981:Molsidomine / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D019335:Nitroarginine / Q000037:antagonists & inhibitors; D010300:Parkinson Disease / Q000188:drug therapy; D051381:Rats; D017208:Rats, Wistar; D014665:Vasodilator Agents / Q000494:pharmacology
D014665:Vasodilator Agents; D019335:Nitroarginine; D001120:Arginine; D008981:Molsidomine; D019001:Nitric Oxide Synthase; D006220:Haloperidol